These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

493 related articles for article (PubMed ID: 26104852)

  • 1. Can echocardiography and ECG discriminate hereditary transthyretin V30M amyloidosis from hypertrophic cardiomyopathy?
    Gustavsson S; Granåsen G; Grönlund C; Wiklund U; Mörner S; Henein M; Suhr OB; Lindqvist P
    Amyloid; 2015; 22(3):163-70. PubMed ID: 26104852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Right ventricular involvement in transthyretin amyloidosis.
    Arvidsson S; Henein MY; Wikström G; Suhr OB; Lindqvist P
    Amyloid; 2018 Sep; 25(3):160-166. PubMed ID: 30193533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective.
    Rapezzi C; Quarta CC; Obici L; Perfetto F; Longhi S; Salvi F; Biagini E; Lorenzini M; Grigioni F; Leone O; Cappelli F; Palladini G; Rimessi P; Ferlini A; Arpesella G; Pinna AD; Merlini G; Perlini S
    Eur Heart J; 2013 Feb; 34(7):520-8. PubMed ID: 22745357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transthyretin amyloidosis: a phenocopy of hypertrophic cardiomyopathy.
    Vermeer AMC; Janssen A; Boorsma PC; Mannens MMAM; Wilde AAM; Christiaans I
    Amyloid; 2017 Jun; 24(2):87-91. PubMed ID: 28475415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combining ECG and echocardiography to identify transthyretin cardiac amyloidosis in heart failure.
    Löfbacka V; Suhr OB; Pilebro B; Wixner J; Sundström T; Lindmark K; Anan I; Lindqvist P
    Clin Physiol Funct Imaging; 2021 Sep; 41(5):408-416. PubMed ID: 34033209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relation of regional myocardial structure and function in hypertrophic cardiomyopathy and amyloidois: a combined two-dimensional speckle tracking and cardiovascular magnetic resonance analysis.
    Pagourelias ED; Mirea O; Vovas G; Duchenne J; Michalski B; Van Cleemput J; Bogaert J; Vassilikos VP; Voigt JU
    Eur Heart J Cardiovasc Imaging; 2019 Apr; 20(4):426-437. PubMed ID: 30085025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differentiating cardiac amyloidosis and hypertrophic cardiomyopathy by use of three-dimensional speckle tracking echocardiography.
    Baccouche H; Maunz M; Beck T; Gaa E; Banzhaf M; Knayer U; Fogarassy P; Beyer M
    Echocardiography; 2012 Jul; 29(6):668-77. PubMed ID: 22486396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of Transthyretin Cardiac Amyloidosis Using Serum Retinol-Binding Protein 4 and a Clinical Prediction Model.
    Arvanitis M; Koch CM; Chan GG; Torres-Arancivia C; LaValley MP; Jacobson DR; Berk JL; Connors LH; Ruberg FL
    JAMA Cardiol; 2017 Mar; 2(3):305-313. PubMed ID: 28196196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Right ventricular myocardial involvement in either physiological or pathological left ventricular hypertrophy: an ultrasound speckle-tracking two-dimensional strain analysis.
    D'Andrea A; Caso P; Bossone E; Scarafile R; Riegler L; Di Salvo G; Gravino R; Cocchia R; Castaldo F; Salerno G; Golia E; Limongelli G; De Corato G; Cuomo S; Pacileo G; Russo MG; Calabrò R
    Eur J Echocardiogr; 2010 Jul; 11(6):492-500. PubMed ID: 20551250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differentiation of cardiac amyloidosis and hypertrophic cardiomyopathy. A comparison of familial amyloidosis with polyneuropathy and hypertrophic cardiomyopathy by electrocardiography and echocardiography.
    Eriksson P; Backman C; Eriksson A; Eriksson S; Karp K; Olofsson BO
    Acta Med Scand; 1987; 221(1):39-46. PubMed ID: 3565084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Hypertrophic cardiomyopathy with dilatation of the left ventricle and congestive heart failure: comparison with postmyocarditis cardiomegaly and hypertensive heart failure].
    Kawanishi H; Yokota Y; Hayakawa M; Kaku K; Kumaki T; Matsumoto K; Fujitani K; Ito Y; Inoh T; Fukuzaki H
    J Cardiogr; 1983 Sep; 13(3):537-50. PubMed ID: 6235295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Usefulness of Combining Electrocardiographic and Echocardiographic Findings and Brain Natriuretic Peptide in Early Detection of Cardiac Amyloidosis in Subjects With Transthyretin Gene Mutation.
    Di Bella G; Minutoli F; Piaggi P; Casale M; Mazzeo A; Zito C; Oreto G; Baldari S; Vita G; Pingitore A; Khandheria BK; Carerj S
    Am J Cardiol; 2015 Oct; 116(7):1122-7. PubMed ID: 26253999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced left atrial myocardial deformation irrespective of cavity size: a potential cause for atrial arrhythmia in hereditary transthyretin amyloidosis.
    Henein MY; Suhr OB; Arvidsson S; Pilebro B; Westermark P; Hörnsten R; Lindqvist P
    Amyloid; 2018 Mar; 25(1):46-53. PubMed ID: 29369708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis.
    Rapezzi C; Quarta CC; Guidalotti PL; Pettinato C; Fanti S; Leone O; Ferlini A; Longhi S; Lorenzini M; Reggiani LB; Gagliardi C; Gallo P; Villani C; Salvi F
    JACC Cardiovasc Imaging; 2011 Jun; 4(6):659-70. PubMed ID: 21679902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differentiation of infiltrative cardiomyopathy from hypertrophic cardiomyopathy using high-sensitivity cardiac troponin T: a case-control study.
    Kubo T; Baba Y; Hirota T; Tanioka K; Yamasaki N; Yamanaka S; Iiyama T; Kumagai N; Furuno T; Sugiura T; Kitaoka H
    BMC Cardiovasc Disord; 2015 Jun; 15():53. PubMed ID: 26077897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early changes in apical rotation in genotype positive children with hypertrophic cardiomyopathy mutations without hypertrophic changes on two-dimensional imaging.
    Forsey J; Benson L; Rozenblyum E; Friedberg MK; Mertens L
    J Am Soc Echocardiogr; 2014 Feb; 27(2):215-21. PubMed ID: 24325958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myocardial Work Appraisal in Transthyretin Cardiac Amyloidosis and Nonobstructive Hypertrophic Cardiomyopathy.
    de Gregorio C; Trimarchi G; Faro DC; De Gaetano F; Campisi M; Losi V; Zito C; Tamburino C; Di Bella G; Monte IP
    Am J Cardiol; 2023 Dec; 208():173-179. PubMed ID: 37852127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differentiation of light-chain cardiac amyloidosis from hypertrophic cardiomyopathy using myocardial mechanical parameters by velocity vector imaging echocardiography.
    Zhang L; Zhou X; Wang J; Mu Y; Liu B; Lv W; Wang Y; Liu H; Liu H; Zhi G
    Int J Cardiovasc Imaging; 2017 Apr; 33(4):499-507. PubMed ID: 27878699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Noninvasive risk stratification of patients with transthyretin amyloidosis.
    Kristen AV; Scherer K; Buss S; aus dem Siepen F; Haufe S; Bauer R; Hinderhofer K; Giannitsis E; Hardt S; Haberkorn U; Katus HA; Steen H
    JACC Cardiovasc Imaging; 2014 May; 7(5):502-10. PubMed ID: 24726252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Value of assessing left ventricular longitudinal systolic peak strain in differential diagnosis of primary cardiac amyloidosis from hypertrophic cardiomyopathy].
    Zhang L; Wang Y; Cheng L; Wang J; Zhou X; Liu M; Zhang W; Zhang M; Zhang B; Zhi G
    Nan Fang Yi Ke Da Xue Xue Bao; 2014 May; 34(5):609-16. PubMed ID: 24849421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.